ArticleFrontiers in aging neuroscience2025
Implications of heart rate variability measured using wearable electrocardiogram devices in diagnosing Parkinson's disease and its association with neuroimaging biomarkers: a case-control study.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The brain and heart-axis in neurodegeneration and cardiovascular disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Artificial intelligence in neurocardiology: decoding brain-heart network interactions for clinical and translational insights.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Heart rate variability (HRV) reflects cardiac autonomic regulation, and reduced HRV is associated with Parkinson's disease (PD). However, studies regarding the implications of HRV measures for the clinical manifestations of PD have shown inconclusive results. We examined the relationship between HRV measures obtained via long-term monitoring using a wearable electrocardiogram (ECG) device and the diagnosis and clinical characteristics of PD. Methods: Seventeen controls and 20 patients with PD were prospectively enrolled. The HRV measures were recorded using a wearable ECG device for up to 72 h. Time- and frequency-domain measures were derived from the HRV analysis, and their association with PD diagnosis and clinical features was investigated. We investigated their association with neuroimaging biomarkers using magnetic resonance imaging to explore the underlying neural correlates. Results: The diagnosis of PD was associated with several HRV measures, including a decreased standard deviation of N-N intervals, standard deviation of all heart rates, and low-frequency (LF) power. Among these HRV measures, only LF power was associated with clinical features of PD. LF power was positively correlated with the tremor sub-score ( Conclusion: Low-frequency power may be used as a biomarker for tremor-associated pathophysiology of PD. Moreover, a wearable ECG device with its capability for long-term monitoring might be a promising tool for diagnosing PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.